Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.verified

IONS

Price:

$36.08

Market Cap:

$5.70B

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with ...[Read more]

Industry

Biotechnology

IPO Date

1991-05-17

Stock Exchange

NASDAQ

Ticker

IONS

The Enterprise Value as of December 2024 (TTM) for Ionis Pharmaceuticals, Inc. (IONS) is 6.81B

According to Ionis Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 6.81B. This represents a change of -14.83% compared to the average of 7.99B of the last 4 quarters.

Ionis Pharmaceuticals, Inc. (IONS) Historical Enterprise Value (quarterly & annually)

How has IONS Enterprise Value performed in the past?

The mean historical Enterprise Value of Ionis Pharmaceuticals, Inc. over the last ten years is 6.07B. The current 6.81B Enterprise Value has changed 11.12% with respect to the historical average. Over the past ten years (40 quarters), IONS's Enterprise Value was at its highest in in the March 2019 quarter at 11.53B. The Enterprise Value was at its lowest in in the June 2016 quarter at 3.17B.

Quarterly (TTM)
Annual

Average

6.07B

Median

6.21B

Minimum

3.34B

Maximum

8.30B

Ionis Pharmaceuticals, Inc. (IONS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Ionis Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 77.44%

Maximum Annual Enterprise Value = 8.30B

Minimum Annual Increase = -50.56%

Minimum Annual Enterprise Value = 3.34B

Quarterly (TTM)
Annual
YearEnterprise ValueChange
20238.30B75.97%
20224.72B41.30%
20213.34B-50.56%
20206.75B1.25%
20196.67B18.27%
20185.64B-1.93%
20175.75B2.41%
20165.61B-19.88%
20157.01B1.35%
20146.91B77.44%

Ionis Pharmaceuticals, Inc. (IONS) Average Enterprise Value

How has IONS Enterprise Value performed in the past?

The current Enterprise Value of Ionis Pharmaceuticals, Inc. (IONS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

5.45B

5-year avg

5.95B

10-year avg

6.07B

Ionis Pharmaceuticals, Inc. (IONS) Enterprise Value vs. Peers

How is IONS’s Enterprise Value compared to its peers?

Ionis Pharmaceuticals, Inc.’s Enterprise Value is less than Arrowhead Pharmaceuticals, Inc. (0), greater than BioMarin Pharmaceutical Inc. (2.87B), less than Incyte Corporation (12.56B), less than Apellis Pharmaceuticals, Inc. (12.19B), greater than Viking Therapeutics, Inc. (4.20B), greater than Intercept Pharmaceuticals, Inc. (4.67B), greater than Terns Pharmaceuticals, Inc. (915.81M), greater than Akero Therapeutics, Inc. (234.86M), greater than Reata Pharmaceuticals, Inc. (1.70B), greater than Seagen Inc. (6.64B), less than Alnylam Pharmaceuticals, Inc. (42.84B), less than Exelixis, Inc. (31.45B), less than Halozyme Therapeutics, Inc. (9.50B), less than PTC Therapeutics, Inc. (7.35B), greater than Krystal Biotech, Inc. (3.39B), greater than Sarepta Therapeutics, Inc. (4.25B), less than Iovance Biotherapeutics, Inc. (12.73B), greater than Madrigal Pharmaceuticals, Inc. (2.19B), greater than null (6.67B),

Build a custom stock screener for Ionis Pharmaceuticals, Inc. (IONS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ionis Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Ionis Pharmaceuticals, Inc. (IONS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Ionis Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Ionis Pharmaceuticals, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Ionis Pharmaceuticals, Inc. (IONS)?

What is the 3-year average Enterprise Value for Ionis Pharmaceuticals, Inc. (IONS)?

What is the 5-year average Enterprise Value for Ionis Pharmaceuticals, Inc. (IONS)?

How does the current Enterprise Value for Ionis Pharmaceuticals, Inc. (IONS) compare to its historical average?